Can social listening data be used to provide meaningful insights into abuse or inappropriate use of bupropion? (A feasibility analysis) (202115)

First published: 16/01/2015

Last updated: 28/05/2024

Study Finalised

Administrative details

EU PAS number

EUPAS8375

Study ID

48232

DARWIN EU® study

No

Study countries

☐ United States

Study status

Finalised

Research institutions and networks

Institutions

GlaxoSmithKline (GSK)

First published: 01/02/2024

Last updated: 01/02/2024

Institution

Contact details

Study institution contact

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor Pharma.CDR@gsk.com

Study contact

Pharma.CDR@gsk.com

Primary lead investigator

GSK Clinical Disclosure Advisor GSK Clinical Disclosure Advisor

Primary lead investigator

Study timelines

Date when funding contract was signed

Planned: 12/12/2014

Actual: 12/12/2014

Study start date
Planned: 30/01/2015

Actual: 12/12/2014

Date of final study report
Planned: 12/12/2016

Actual: 03/06/2016

Sources of funding

- Pharmaceutical company and other private sector

More details on funding

GlaxoSmithKline

Study protocol

202115-protocol-redact.pdf(510.79 KB)

gsk-202115-protocol-redact.pdf(926.71 KB)

Regulatory

Was the study required by a regulatory body?

No

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)

Methodological aspects

Study type

Study topic:

Human medicinal product

Study type:

Non-interventional study

Scope of the study:

Other

If ‘other’, further details on the scope of the study

Observational feasibility study

Data collection methods:

Secondary use of data

Main study objective:

The purpose of this analysis is to determine the feasibility to use social media for collecting meaningful insights into potential abuse or inappropriate use of bupropion.

Study Design

Non-interventional study design

Other

Non-interventional study design, other

Retrospective descriptive observational study

Study drug and medical condition

Study drug International non-proprietary name (INN) or common name

AMITRIPTYLINE

BUPROPION

CODEINE BP

DIAZEPAM

Population studied

Short description of the study population

Data were collected from publicly available social media or internet forum posts from individuals who chose to post on Bluelight or Opiophile by EpidemicoTM through the DataSiftTM platform or directly from the in-scope website administrators. The population was thus self-selecting and voluntary, and included users from any country or background as long as they posted in the English language and agreed to the site’s policies.

Age groups

Adults (18 to < 46 years)

Adults (46 to < 65 years)

Adults (65 to < 75 years)

Adults (75 to < 85 years)

Adults (85 years and over)

Estimated number of subjects

100

Study design details

Data analysis plan

Bupropion abuse data available will be compared to positive controls—those with established abuse liability greater than bupropion (methyphenidate, alprazolam), negative controls—non-controlled substances with negligible abuse liability, similar to current international classification of bupropion (venlafaxine, amitriptyline), and opioid controls (buprenorphine, oxycodone).

Documents

Study results

gsk-202115-clinical-study-report-redact.pdf(1.56 MB)

Data management

ENCePP Seal

The use of the ENCePP Seal has been discontinued since February 2025. The ENCePP Seal fields are retained in the display mode for transparency but are no longer maintained.

Data sources

Data sources (types)

Other

Data sources (types), other

Social media websites including Facebook, Twitter, erowid.org, reddit.com, drugs-forum.com, hipforums.com, shroomery.org, grasscity.org, reddit.com/r/Drugs, reddit.com/r/Nootropics, IOPlist.com, and partyvibe.org.

Use of a Common Data Model (CDM)

CDM mapping

No

Data quality specifications

Check conformance

Unknown

Check completeness

Unknown

Check stability

Unknown

Check logical consistency

Unknown

Data characterisation

Data characterisation conducted

No